Table of Contents

Small Molecule Therapeutics

• Small Molecule Therapeutics

  Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer

  Krishnendu Pal, Ying Cao, Irina N. Gaisina, Santanu Bhattacharya, Shamit K. Dutta, Enfeng Wang, Hendra Gunosewoyo, Alan P. Kozikowski, Daniel D. Billadeau and Debabrata Mukhopadhyay

  Mol Cancer Ther February 1 2014 13 (2) 285-296; DOI:10.1158/1535-7163.MCT-13-0681

  
  
• Small Molecule Therapeutics

  Bisphosphonamidate Clodronate Prodrug Exhibits Selective Cytotoxic Activity against Melanoma Cell Lines

  Marie R. Webster, Chandrashekhar Kamat, Nick Connis, Ming Zhao, Ashani T. Weeraratna, Michelle A. Rudek, Christine L. Hann and Caren L. Freel Meyers

  Mol Cancer Ther February 1 2014 13 (2) 297-306; DOI:10.1158/1535-7163.MCT-13-0315

  
  
• Small Molecule Therapeutics

  Selective Inhibition of Pancreatic Ductal Adenocarcinoma Cell Growth by the Mitotic MPS1 Kinase Inhibitor NMS-P715

  Roger B. Slee, Brenda R. Grimes, Ruchi Bansal, Jesse Gore, Corinne Blackburn, Lyndsey Brown, Rachel Gasaway, Jaesik Jeong, Jose Victorino, Keith L. March, Riccardo Colombo, Brittney-Shea Herbert and Murray Korc

  Mol Cancer Ther February 1 2014 13 (2) 307-315; DOI:10.1158/1535-7163.MCT-13-0324

  
  
• Small Molecule Therapeutics

  Inhibition of Insulin-like Growth Factor–Binding Protein-3 Signaling through Sphingosine Kinase-1 Sensitizes Triple-Negative Breast Cancer Cells to EGF Receptor Blockade

  Janet L. Martin, Hasanthi C. de Silva, Mike Z. Lin, Carolyn D. Scott and Robert C. Baxter

  Mol Cancer Ther February 1 2014 13 (2) 316-328; DOI:10.1158/1535-7163.MCT-13-0367

  
  
• Small Molecule Therapeutics

  The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice

  Masamichi Mori, Yoko Ueno, Satoshi Konagai, Hiroshi Fushiki, Itsuro Shimada, Yutaka Kondoh, Rika Saito, Kenichi Mori, Nobuaki Shindou, Takatoshi Soga, Hideki Sakagami, Takashi Furutani, Hitoshi Doihara, Masafumi Kudoh and Sadao Kuromitsu

  Mol Cancer Ther February 1 2014 13 (2) 329-340; DOI:10.1158/1535-7163.MCT-13-0395

  
  
• Small Molecule Therapeutics

  A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells

  Karishma S. Amin, Shankar Jagadeesh, Gakul Baishya, Paruchuri G. Rao, Nabin C. Barua, Samir Bhattacharya and Partha P. Banerjee

  Mol Cancer Ther February 1 2014 13 (2) 341-352; DOI:10.1158/1535-7163.MCT-13-0478

  
  
• Small Molecule Therapeutics | AuthorChoice

  Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib

  Jaime Acquaviva, Donald L. Smith, John-Paul Jimenez, Chaohua Zhang, Manuel Sequeira, Suqin He, Jim Sang, Richard C. Bates and David A. Proia

  Mol Cancer Ther February 1 2014 13 (2) 353-363; DOI:10.1158/1535-7163.MCT-13-0481

  
  
• Small Molecule Therapeutics

  Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

  Robert M. Campbell, Bryan D. Anderson, Nathan A. Brooks, Harold B. Brooks, Edward M. Chan, Alfonso De Dios, Raymond Gilmour, Jeremy R. Graff, Enrique Jambrina, Mary Mader, Denis McCann, Songqing Na, Stephen H. Parsons, Susan E. Pratt, Chuan Shih, Louis F. Stancato, James J. Starling, Courtney Tate, Juan A. Velasco, Yong Wang and Xiang S. Ye

  Mol Cancer Ther February 1 2014 13 (2) 364-374; DOI:10.1158/1535-7163.MCT-13-0513